Massachusetts General Hospital, one of the leading institutions in medical research and education, and a foundational constituent of the Mass General Brigham healthcare system, has been excelling in providing expert medical care. The organization diligently treads the path of innovation, amalgamating state-of-the-art clinical practice with cutting-edge scientific research. Recently, an interdisciplinary team at Mass General developed an uncompromisingly efficient computer algorithm named EvalMpox, destined to streamline the detection of a newly emerging infection known as mpox (previously known as monkeypox). This breakthrough was officially announced on April 2, 2024.
In the demanding spectrum of healthcare, the crucial task of diagnosing infectious conditions, particularly uncommon or newly surfacing ones like mpox, demands not only medical prowess but also relies significantly on the technological advancement. This ticklish situation requires reliable diagnostic tools that assist clinicians reduce the disease’s spread by successfully classifying, isolating, and treating patients afflicted with such infections.
Addressing this critical need, Mass General’s investigators led by Dr. Jacob Lazarus rolled out the EvalMpox, an ingenious diagnostic tool, embedded seamlessly into the electronic medical record systems. It functions as a clinical decision support system, instructing clinicians about key elements of physical examination and critical patient inquiries, essential for possible mpox cases. Notably, it proved beneficial in treating patients with a rash symptom.
The effectiveness of EvalMpox was evaluated in over 668 patient visits from upwards of 100 diverse clinical locations covering Greater Boston, Nantucket, Martha’s Vineyard, western Massachusetts, and southern New Hampshire. Based on the responses to potential mpox exposures, symptoms, and the characteristic rash examination, EvalMpox classified patients as ‘likely’ or ‘unlikely’ to have mpox. Statistical analysis revealed that patients classified as likely to have mpox, exhibited similarities with confirmed mpox cases and were, therefore, prioritized for testing. They were significantly more likely to test positive for mpox.
Dr. Erica S. Shenoy, the Chief of Mass General Brigham’s Infection Control and senior author, accredited EvalMpox for accurately identifying nearly all diagnosed mpox cases in the Mass General Brigham system during the study. Also, the tool spelled out a high negative predictive score implying the low chances of a person having the infection when EvalMpox mentioned them to be at low risk for mpox. This predictive reliability underscores the fundamental importance of efficient means to determine when to stop isolation and reassure patients about their unlikely infection state.
Riding on the wave of these promising results, the team now turns its focus toward developing similar tools. Leaning on the insights from the COVID-19 pandemic and the mpox outbreak, they are working on decision support equipment for diagnosing other emerging infections, such as Ebola, Lassa Fever, Marburg Virus Disease, and managing ‘routine’ infections necessitating patient isolation. This initiative is underwritten by a cooperative agreement from the Centers for Disease Control and Prevention, asserting no involvement in the manuscript’s preparation, submission, or review.
In conclusion, the relentless pursuit of groundbreaking research and commitment to healthcare excellence propels institutions like Mass General to pioneer novel methods and enrich the pool of medical knowledge. This hospital’s exploits serve as inspiring bench press highlights, improving human health through the development and application of advanced diagnostics.
Source: https://www.massgeneral.org/news/press-release/emr-tool-diagnosis-of-mpox